Custom Gene Synthesis Service Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Custom Gene Synthesis Service Market is projected to expand from USD 1.59 Billion in 2025 to USD 2.61 Billion by 2031, reflecting a compound annual growth rate of 8.61%. This industry centers on the de novo creation of double-stranded DNA molecules, allowing for the generation of precise genetic sequences independent of natural templates, which is fundamental to genetic engineering in pharmaceuticals, agriculture, and academia. Growth is primarily fueled by the rapid advancement of biologics and the urgent demand for synthetic DNA in personalized medicine and vaccine development. As noted by the American Society of Gene & Cell Therapy, the global pipeline contained over 4,000 gene, cell, and RNA therapies in 2024, highlighting the immense industrial requirement for high-grade synthetic genetic materials.

Despite this expansion, the market faces a substantial hurdle in synthesizing long or complex DNA sequences. Producing sequences with repetitive structures or high GC content via standard chemical methods often leads to lower yields and higher error rates, resulting in increased costs and slower production times. This technical limitation hampers the scalability needed to meet growing industrial demands, potentially restricting broader market growth as researchers increasingly depend on intricate, error-free genetic constructs for sophisticated therapeutic applications.

Market Drivers

The rapid progression of gene and cell therapy development serves as a major engine for the Global Custom Gene Synthesis Service Market. As these advanced treatments move from early research phases to commercial availability, there is an intensifying need for high-quality, GMP-grade synthetic DNA essential for manufacturing plasmids, viral vectors, and guide RNAs. This boom in therapeutic innovation fosters a continuous reliance on synthesis vendors to provide precise genetic constructs at scale, ensuring the supply of vital materials for patient care. This trend is reinforced by regulatory achievements; the U.S. Food and Drug Administration (FDA) approved a record seven new cell and gene therapies in 2023, signaling a maturing pipeline and a widening market necessity for dependable synthetic components.

Simultaneously, technological breakthroughs in automation and DNA synthesis platforms are boosting market value by resolving the constraints of conventional phosphoramidite chemistry. Newer techniques, such as silicon-based automation and enzymatic synthesis, allow for the fast generation of longer, high-fidelity sequences, directly meeting the needs of biologics discovery. These innovations are drawing significant investment to expand production capacities; for instance, Elegen raised $35 million in Series B funding in May 2024 to enhance its cell-free DNA manufacturing. This technological integration is driving financial success, as evidenced by Twist Bioscience, which reported in November 2024 that its synthetic biology revenue had increased to $123.5 million for the fiscal year 2024.

Market Challenges

The difficulty of synthesizing long and complex DNA sequences creates a major technical obstacle that limits the scalability of the global custom gene synthesis service market. Manufacturers struggle to produce sequences with intricate repetitive structures or high GC content, issues that frequently lead to diminished yields and elevated error rates. These technical constraints force providers to incur higher production costs and face longer turnaround times to guarantee accuracy, ultimately impairing operational efficiency. As a result, the inability to deliver these complex constructs rapidly and reliably slows the supply chain, hindering vendors from fully meeting the high-volume needs of academic and pharmaceutical clients requiring specific materials for sensitive projects.

This operational bottleneck severely impedes market growth by causing a disconnect between the accelerating speed of therapeutic research and the availability of synthetic DNA. The industry's struggle to efficiently scale the production of complex sequences restricts its ability to support well-financed development initiatives that rely on timely material delivery. According to SynBioBeta, venture investment in the synthetic biology sector hit 12.2 billion dollars in 2024. While this massive capital inflow indicates strong industrial demand for genetic materials, persistent difficulties in effectively synthesizing complex sequences prevent the market from fully realizing its growth potential in proportion to this investment.

Market Trends

Artificial intelligence is fundamentally transforming the market by optimizing the design phase of synthetic biology through sequence enhancement. AI algorithms are increasingly utilized to predict structural stability and optimize codon usage prior to physical synthesis, effectively lowering failure rates and speeding up the design-build-test cycle for therapeutic candidates. This shift toward computational design is driving significant demand for synthetic constructs needed to physically validate algorithmic models. In April 2024, Xaira Therapeutics announced it had secured $1 billion in committed capital to further AI-driven drug discovery, a massive investment that highlights the industry's growing dependence on high-throughput gene synthesis to verify protein designs generated by AI.

In parallel, the rise of DNA data storage is broadening the market's reach beyond traditional life sciences. With global digital data production exceeding conventional storage capabilities, synthetic DNA is gaining traction as a high-density, durable medium for long-term archiving. This application is moving from theoretical research to commercial viability, opening a new avenue for synthesis providers to encode digital data into genetic sequences. For example, in January 2024, Biomemory launched the world's first commercially available DNA storage product with a 1-kilobyte capacity, proving the practical feasibility and initial commercialization of this technology for archival needs.

Key Players Profiled in the Custom Gene Synthesis Service Market

• GenScript Biotech Corporation
• Biomatik Corporation
• Thermo Fisher Scientific Inc.
• Integrated DNA Technologies, Inc.
• Synbio Technologies LLC
• Biomol GmbH
• Eurofins Genomics Germany GmbH
• BioCat GmbH
• Azenta US Inc.
• ProMab Biotechnologies, Inc.

Report Scope

In this report, the Global Custom Gene Synthesis Service Market has been segmented into the following categories:

Custom Gene Synthesis Service Market, by Type:

• Below 1000 bp
• 1001 to 3000 bp
• 3001 to 5000 bp
• above 5000 bp

Custom Gene Synthesis Service Market, by Application:

• Commercial
• Academic Research

Custom Gene Synthesis Service Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Custom Gene Synthesis Service Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.